Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J H Meuleman

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Urologic Oncology|August 28, 2014
Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?André N Vis, Tim M van der Sluis, Hoda H M Al-Itejawi, et al.
International Journal of Impotence Research|February 28, 2003
Prognostic factors for the vascular components of erectile dysfunction in patients on renal replacement therapyW L Diemont, J C M Hendriks, W A J G Lemmens, et al.
European Journal of Endocrinology|February 13, 2009
Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled studyJean-Jacques Legros, Eric J H Meuleman, Jolanda M H Elbers, et al.
BMC Urology|June 3, 2014
Development of an in vitro model to measure bioactivity of botulinum neurotoxin A in rat bladder muscle stripsJanneke I M van Uhm, Goedele M A Beckers, Willem J van der Laarse, et al.
BJU International|October 14, 2011
Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancerTim M van der Sluis, André N Vis, R Jeroen A van Moorselaar, et al.
BJU International|October 14, 2011
Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancerTim M van der Sluis, Eric J H Meuleman, R Jeroen A van Moorselaar, et al.
Urology|March 8, 2013
Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancerTim M van der Sluis, R Jeroen A van Moorselaar, Eric J H Meuleman, et al.
The Aging Male : the Official Journal of the International Society for the Study of the Aging Male|April 16, 2013
Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging studyPierre M G Bouloux, Jean-Jacques Legros, Jolanda M H Elbers, et al.
European Urology Focus|April 27, 2019
Effectiveness of Preoperative Depilation of the Urethral Donor Site for Phalloplasty: Neourethral Hair Growth and its Effects on VoidingGarry L S Pigot, Saloua Belboukhaddaoui, Mark Bram Bouman, et al.
The Journal of Clinical Endocrinology and Metabolism|June 28, 2007
Testicular tumors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency show functional features of adrenocortical tissueHedi L Claahsen-van der Grinten, Barto J Otten, Fred C G J Sweep, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Urologic Oncology|August 28, 2014
Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?André N Vis, Tim M van der Sluis, Hoda H M Al-Itejawi, et al.
International Journal of Impotence Research|February 28, 2003
Prognostic factors for the vascular components of erectile dysfunction in patients on renal replacement therapyW L Diemont, J C M Hendriks, W A J G Lemmens, et al.
European Journal of Endocrinology|February 13, 2009
Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled studyJean-Jacques Legros, Eric J H Meuleman, Jolanda M H Elbers, et al.
BMC Urology|June 3, 2014
Development of an in vitro model to measure bioactivity of botulinum neurotoxin A in rat bladder muscle stripsJanneke I M van Uhm, Goedele M A Beckers, Willem J van der Laarse, et al.
BJU International|October 14, 2011
Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancerTim M van der Sluis, André N Vis, R Jeroen A van Moorselaar, et al.
BJU International|October 14, 2011
Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancerTim M van der Sluis, Eric J H Meuleman, R Jeroen A van Moorselaar, et al.
Urology|March 8, 2013
Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancerTim M van der Sluis, R Jeroen A van Moorselaar, Eric J H Meuleman, et al.
The Aging Male : the Official Journal of the International Society for the Study of the Aging Male|April 16, 2013
Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging studyPierre M G Bouloux, Jean-Jacques Legros, Jolanda M H Elbers, et al.
European Urology Focus|April 27, 2019
Effectiveness of Preoperative Depilation of the Urethral Donor Site for Phalloplasty: Neourethral Hair Growth and its Effects on VoidingGarry L S Pigot, Saloua Belboukhaddaoui, Mark Bram Bouman, et al.
The Journal of Clinical Endocrinology and Metabolism|June 28, 2007
Testicular tumors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency show functional features of adrenocortical tissueHedi L Claahsen-van der Grinten, Barto J Otten, Fred C G J Sweep, et al.
Pageof 5